Table 2

Cox regression analysis for cPFS and OS for entire cohort of patients with advanced melanoma

cPFS univariablecPFS multivariableOS univariableOS multivariable
HR95% CIP valueHR95% CIP valueHR95% CIP valueHR95% CIP value
Primary tumor type
 Acral or mucosal vs cutaneous or unknown1.571.09 to 2.260.0161.851.23 to 2.790.0031.841.23 to 2.760.0032.131.36 to 3.340.001
Genomic subtype
 BRAF or NRAS mt vs WT1.280.94 to 1.770.1201.400.99 to 1.960.0561.160.81 to 1.650.4231.461.00 to 2.130.052
Anti-PD1 regimen
 PD1+CTLA4 vs PD10.630.45 to 0.900.0110.570.38 to 0.860.0070.600.40 to 0.900.0140.420.28 to 0.65<0.001
Line of therapy
 First vs second or later0.560.42 to 0.76<0.0010.720.51 to 1.010.0620.530.38 to 0.75<0.001
No of metastatic sites
 >3 vs ≤32.151.56 to 2.98<0.0012.061.47 to 2.88<0.0012.231.56 to 3.18<0.0012.161.50 to 3.11<0.001
M-stage
 M1c/1d vs M0/1a/1b1.451.06 to 2.000.0221.791.24 to 2.570.002
LDH
 ≥1.5X ULN vs <1.5 x1.831.32 to 2.54<0.0011.491.06 to 2.110.0232.411.68 to 3.46<0.0011.881.28 to 2.76<0.001
NLR
 ≥5 vs <51.390.98 to 1.960.0621.721.19 to 2.510.0041.591.06 to 2.360.023
Age
 ≥60 vs <600.830.61 to 1.110.2151.210.86 to 1.710.267
Gender
 Male vs female0.780.58 to 1.060.1140.820.58 to 1.150.254
  • cPFS, clinical progression-free survival; LDH, lactate dehydrogenase; NLR, neutrophil to lymphocyte ratio; OS, overall survival.